Tag Archives: Difei Yang

Mizuho Securities Releases a Buy Rating on Heron Therapeutics

In a report released today, Difei Yang from Mizuho Securities assigned a Buy rating to Heron Therapeutics (NASDAQ: HRTX), with a price target of $28. The company’s shares closed yesterday at $15.45. Yang said: “We analyze in greater detail Heron

Mizuho Securities Releases a Buy Rating on Zogenix

Mizuho Securities analyst Difei Yang assigned a Buy rating to Zogenix (NASDAQ: ZGNX) today and set a price target of $51. The company’s shares closed yesterday at $34.10. Yang commented: “We found the safety data to be adequate, with no

Revance Therapeutics Received its Third Buy in a Row

After Cantor Fitzgerald and Piper Jaffray assigned a Buy rating to Revance Therapeutics in the last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang initiated coverage with a Buy rating on Revance Therapeutics (NASDAQ:

Analysts Offer Insights on Healthcare Companies: Viewray (NASDAQ: VRAY) and Crispr Therapeutics AG (NASDAQ: CRSP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viewray (NASDAQ: VRAY) and Crispr Therapeutics AG (NASDAQ: CRSP). Viewray (NASDAQ: VRAY) Mizuho Securities analyst Difei Yang assigned a Buy rating to Viewray

Mizuho Securities Believes Nektar Therapeutics (NASDAQ: NKTR) Won’t Stop Here

Mizuho Securities analyst Difei Yang assigned a Buy rating to Nektar Therapeutics (NASDAQ: NKTR) today. The company’s shares closed on Friday at $32.50, close to its 52-week high of $33.67. Yang wrote: “We believe raising our PT from $30 to

Mizuho Securities Issues a Hold Rating on FibroGen

In a report released today, Difei Yang from Mizuho Securities assigned a Hold rating to FibroGen (NASDAQ: FGEN), with a price target of $61. The company’s shares closed yesterday at $54.05, close to its 52-week high of $60.15. Yang observed: